Successfully promote hair regrowth! Eli Lilly's JAK inhibitor reaches phase 3 clinical endpoint

Today, Eli Lilly and Company and Incyte jointly announced that the oral JAK inhibitor baricitinib has reached the primary endpoint in a phase 3 clinical trial for the treatment of adult patients with severe alopecia areata (alopecia areata).

Alopecia areata is the second highest incidence of hair loss in the world.

Baricitinib is an oral JAK inhibitor.

In this randomized, double-blind, placebo-controlled Phase 3 clinical study called BRAVE-AA2, 546 patients with severe alopecia areata (more than 50% of their hair loss) received treatment with baricitinib or placebo.

The results of the trial showed that the two different doses of baricitinib reached the primary endpoint of the trial at 36 weeks, and the safety profile was consistent with the safety profile in the treatment of patients with rheumatoid arthritis and atopic dermatitis.

"For patients with alopecia areata, this is not just a disease that affects appearance, but a serious autoimmune disease that can have a significant psychological impact.

In the treatment of alopecia areata, JAK inhibitors are the first treatment that is expected to achieve a breakthrough.

In addition, Concert Pharmaceuticals' CTP-543 is an oral JAK1/2 inhibitor.

In China, the JAK small molecule inhibitor Jacketinib independently developed by Zejing Bio has also entered clinical trials as a cream for the treatment of mild to moderate alopecia areata.

Note: This article is intended to introduce medical and health research, not a treatment plan recommendation.

Reference materials:

[1] Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial.